Trihexyphenidyl
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Trihexyphenidyl: From Parkinson Disease to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Trihexyphenidyl is a central anticholinergic drug originally used to treat Parkinson disease and related movement disorders such as dystonia. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), but this rests on a computational prediction only: 0 clinical trials and 1 loosely related publication (on tic disorder with dystonia, not ADHD treatment) are currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson disease and related parkinsonian and dystonic disorders (the Singapore licence has no indication text recorded) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, trihexyphenidyl is a central muscarinic antagonist with a preference for the M1 receptor. It modulates the balance between cholinergic and dopaminergic signalling in the striatum, which is the basis for its use in Parkinson disease and dystonia.
ADHD involves dopaminergic and noradrenergic dysregulation, so an indirect link through striatal neurotransmitter balance is conceivable. However, anticholinergic drugs typically impair attention and cognition, which argues against benefit and may even worsen inattention. The only retrieved paper concerns tic disorder with dystonia, a related movement phenotype, and does not test trihexyphenidyl in ADHD. The very high TxGNN score therefore reflects a knowledge-graph association rather than clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21506147 | 2011 | Cohort | Movement Disorders | Large clinical series of patients with tics and persistent dystonia, describing the prevalence and clinical features of this combined syndrome. It does not evaluate trihexyphenidyl for ADHD. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05827P | AA Pharma Trihexyphenidyl Tablet 2 mg (Apotex Inc) | Tablet | Not recorded in the available data |
Safety Considerations
- Contraindications (from knowledge-graph associations, not package insert text): The drug is linked to contraindication with angle-closure and open-angle glaucoma, benign prostatic hyperplasia, myasthenia gravis, paralytic ileus, achalasia, ulcerative colitis and inflammatory bowel disease, hiatus hernia, and several cardiovascular conditions (hypertension, hypotension, coronary artery disease, heart conduction disease, sudden cardiac arrest). It is also linked to chronic obstructive pulmonary disease, kidney disease, liver disease, gallbladder disease, gastric ulcer and Clostridium difficile colitis.
- Drug Interactions (100 interactions were found; the main ones are listed):
- Major: potassium chloride and potassium citrate.
- Moderate: other anticholinergic or antimuscarinic agents (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine, trospium, propantheline, methscopolamine, mepenzolate), opioids and gut-motility agents (morphine, loperamide, eluxadoline), prokinetics (metoclopramide, prucalopride), pramlintide, cannabinoids (dronabinol, nabilone) and magnesium hydroxide.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported by model score alone, with no registered trials and no ADHD-specific literature. The pharmacology (central anticholinergic effects that can impair attention and cognition) argues against benefit, and the safety profile includes many potential contraindications and anticholinergic drug interactions.
To proceed, the following is needed:
- Singapore package insert warnings and contraindications (currently a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Preclinical or clinical evidence on trihexyphenidyl in ADHD, including its cognitive effects
- Review of the other predicted indications, particularly PLA2G6-associated neurodegeneration, which overlaps most closely with the drug's parkinsonian and dystonic uses. It is a research question at evidence level L4, based on an indirect case report only.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.